Chart Events
Performance Outlook
| Previous Close | 0.0960 |
| Open | 0.0970 |
| Bid | 0.0960 x 0 |
| Ask | 0.0970 x 0 |
| Day's Range | 0.0970 - 0.0980 |
| 52 Week Range | 0.0540 - 0.1380 |
| Volume | 121,200 |
| Avg. Volume | 511,117 |
| Market Cap | 76.746M |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0040 |
| Earnings Date | Aug 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Serial Healthcare Entrepreneur Amir Belson, M.D. Joins Ceretrieve as Chairman
Ceretrieve, a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), a leading Israel- and Singapore-based investment group focused on high-growth medical and agrifood technologies, announced that it has appointed Amir Belson M.D. as chairman following the company's close of $1.5 million in funding.
- PR Newswire
Vvital Biomed Announces Stellar Advisory Board
Vvital Biomed ("Vvital"), a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), a leading Israel- and Singapore-based investment group focused on high-growth medical and agrifood technologies, announced that three world-renowned cardiologists have recently joined the advisory board of Vvital, strengthening the company's capabilities to build its solution for mitral and tricuspid valve repair.
- PR Newswire
Limaca Medical Raises $1.25 Million to Enhance Precision Medicine Through Improved Biopsies
Limaca Medical, ("Limaca") a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), a leading Israel- and Singapore-based investment group focused on high-growth medical and agrifood technologies, announced it has closed $1.25 million of a $1.5 million round to complete first-in-human ("FIH") procedures, post-market clinical studies, and obtain regulatory approvals.
